Wall Street Analysts Predict a 34.41% Upside in Kymera Therapeutics (KYMR): Here's What You Should KnowZacks Investment Research • 05/03/24
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business UpdateGlobeNewsWire • 05/02/24
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/25/24
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual MeetingGlobeNewsWire • 04/08/24
Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have FaithSeeking Alpha • 03/21/24
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual MeetingGlobeNewsWire • 03/08/24
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 02/22/24
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 02/15/24
Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22GlobeNewsWire • 02/15/24
Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare ConferenceGlobeNewsWire • 01/31/24
Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology ProgramsGlobeNewsWire • 01/09/24
Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 01/09/24
Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million OfferingInvestors Business Daily • 01/05/24
R&D Day Highlights Kymera's Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory DiseasesGlobeNewsWire • 01/04/24
Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024GlobeNewsWire • 01/02/24
Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual MeetingGlobeNewsWire • 12/11/23
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from SanofiGlobeNewsWire • 12/07/23
Soros snaps up tech stocks in Q3, but dumps some of the biggest names, along with RivianMarket Watch • 11/14/23